ProEthic Pharmaceuticals, Inc. Announces Filing of New Drug Application for Migraine Product Candidate

MONTGOMERY, Ala.--(BUSINESS WIRE)--ProEthic Pharmaceuticals, Inc., a privately funded specialty pharmaceutical company that acquires, develops, licenses, and markets niche prescription products, today announced that it has submitted a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for PRO-513, its lead product candidate for the treatment of migraine headaches. The basis for the NDA is positive outcomes from two randomized, well-controlled Phase III clinical trials in migraine sufferers.

MORE ON THIS TOPIC